NADAC acquisition cost data for SANCUSO 3.1 MG/24 HR PATCH. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 42747072601 | $591.02 | 2022-06-23 | Rx |
| 42747072601 | $591.02 | 2022-06-23 | Rx |
| 42747072601 | $591.02 | 2022-06-23 | Rx |
| 42747072601 | $591.02 | 2022-06-23 | Rx |
| 42747072601 | $591.02 | 2022-06-23 | Rx |
| 42747072601 | $591.02 | 2022-06-23 | Rx |
| 42747072601 | $591.02 | 2022-06-23 | Rx |
| 42747072601 | $591.02 | 2022-06-23 | Rx |
| 42747072601 | $591.02 | 2022-06-23 | Rx |
| 42747072601 | $591.02 | 2022-06-23 | Rx |
Generic: Granisetron | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $9.2M | 5,905 | 2,150 | $562.86 |
| 2020 | $8.0M | 4,816 | 1,606 | $588.00 |
| 2021 | $7.6M | 3,910 | 1,435 | $623.51 |
| 2022 | $7.2M | 3,565 | 1,259 | $661.77 |
| 2023 | $6.8M | 3,201 | 1,178 | $693.67 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $734.7K | 363 | 157 |
| Pennsylvania | $690.4K | 280 | 84 |
| Alabama | $669.5K | 247 | 126 |
| New Jersey | $663.0K | 415 | 125 |
| Texas | $522.1K | 328 | 130 |
| New York | $473.0K | 206 | 75 |
| Kentucky | $376.9K | 87 | 27 |
| Indiana | $318.1K | 117 | 31 |
| Michigan | $249.8K | 103 | 31 |
| Florida | $212.1K | 88 | 37 |
| North Carolina | $204.8K | 81 | 41 |
| Georgia | $180.9K | 79 | 32 |
| Maryland | $178.9K | 86 | 29 |
| Virginia | $152.9K | 104 | 27 |
| Tennessee | $142.0K | 66 | 22 |
| South Carolina | $130.8K | 76 | 24 |
| Colorado | $119.1K | 64 | 19 |
| Illinois | $98.3K | 36 | 12 |
| Ohio | $88.9K | 44 | 16 |
| Washington | $80.1K | 30 | N/A |
| Louisiana | $79.7K | 45 | 20 |
| Connecticut | $55.2K | 28 | 12 |
| Wisconsin | $54.2K | 23 | N/A |
| Hawaii | $43.5K | 48 | 19 |
| Missouri | $36.5K | 31 | 16 |
| Minnesota | $33.6K | 14 | N/A |
| Arizona | $24.5K | 18 | N/A |
| Oklahoma | $16.7K | 11 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.